Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

T-cell engagers in mAPMR/mCRPC prostate cancer

ESMO 2026

23 - 27 Oct 2026

Published: 25 Oct 2026

Views: 61

Rating:

Save

Dr Dominik Berthold - Centre Hospitalier Universitaire Vaudois—CHUV, Lausanne, Switzerland

Dr Dominik Berthold updates ecancer at ESMO 2026 about a new area of potential treatment using bispecific T-cell engagers.

This emerging class of targeted immunotherapies is being investigated for advanced prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC, also known as metastatic androgen pathway modulation-resistant prostate cancer) and neuroendocrine prostate cancer (NEPC).

Related Videos

Perioperative pembrolizumab fails to significantly improve event-free survival in muscle-invasive bladder cancer

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany

Perioperative pembrolizumab fails to significantly improve event-free survival in muscle-invasive bladder cancer ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC

Dr Rahul Aggarwal - University of California, San Francisco, USA

Novel therapies in mCRPC: Tarlatamab targeting DLL3 shows early activity in neuroendocrine mCRPC ( Dr Rahul Aggarwal - University of California, San Francisco, USA )

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma

Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA

Adjuvant avelumab reduces relapse risk in stage III Merkel cell carcinoma ( Dr Shailender Bhatia - Fred Hutchinson Cancer Center, Seattle, USA )

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma ( Dr Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer ( Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain )

ESMO 2025: Prostate highlights

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina

ESMO 2025: Prostate highlights ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC

Dr David Braun - Yale School of Medicine, New Haven, USA

HPK1 inhibitor NDI-101150 shows safety and antitumour activity in ccRCC ( Dr David Braun - Yale School of Medicine, New Haven, USA )

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy

Dr Sarah Psutka - University of Washington, Seattle, USA

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy ( Dr Sarah Psutka - University of Washington, Seattle, USA )

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC

Prof Camillo Porta - University of Bari, Bari, Italy,

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta - University of Bari, Bari, Italy, )

More from ecancer